Aceclidine
Brand names: Vizz ยท Active ingredient: Aceclidine Hydrochloride
In short: VIZZ is indicated for the treatment of presbyopia in adults.
What is Aceclidine used for?
VIZZ is indicated for the treatment of presbyopia in adults.
Aceclidine dosage
Instill one drop in each eye, wait 2 minutes and instill a second drop in each eye once daily from the same single-dose vial.
Contact lenses should be removed prior to the instillation of VIZZ and may be reinserted 10 minutes after instillation.
If more than one topical ophthalmic product is being used, the products should be administered at least 5 minutes apart.
To open vial, twist off top
.
Discard the opened single-dose vial after use.
How to take Aceclidine โ instructions & advice from the label
Night Driving
Advise patients that they may experience temporary dim or dark vision. Advise patients to exercise caution with night driving and when hazardous activities are undertaken in poor illumination
.
Blurred Vision
Temporary problems when changing focus between near and distant objects may occur. Advise patients not to drive or use machinery if vision is not clear (e.g., blurred vision)
.
When to Seek Physician Advice
Advise patients to seek immediate medical care with sudden onset of flashing lights, floaters, or vision loss
.
Contact Lens Wear
Advise patients to remove contact lenses prior to the instillation of VIZZ. Wait 10 minutes after instillation before reinserting their contact lenses
.
Potential for Eye Injury or Contamination
Advise patients to avoid touching the tip of the single-dose vial to the eye or to any other surface in order to prevent eye injury or contamination
.
Advise patients to discard the opened single-dose vial and any remaining contents after use.
Concomitant Topical Ocular Therapy
Advise patients if more than one topical ophthalmic medication is being used, the medicines should be administered at least 5 minutes apart
.
Warnings & precautions
Do not take this medicine if: None.
Miotics may cause accommodative spasm. Do not drive or operate machinery if vision is not clear (e.g., blurred vision).
Patients may experience temporary dim or dark vision. Exercise caution in night driving and other hazardous activities in poor illumination.
Rare cases of retinal tear and detachment have been reported with miotics when used in susceptible individuals and those with pre-existing retinal disease. Examination of the retina is advised in all patients prior to the initiation of treatment with VIZZ. Patients should be advised to seek immediate care with sudden onset of flashing lights, floaters, or vision loss.
Sequelae of ocular inflammation, i.e., adhesions (synechiae) between the iris and the lens, may be exacerbated with miotic use in patients with a known history of iritis.
VIZZ is not recommended for use in patients with a known hypersensitivity to aceclidine or any other ingredient in VIZZ.
Contact lenses should be removed prior to the instillation of VIZZ and may be reinserted 10 minutes after instillation.
To prevent eye injury or contamination, care should be taken to avoid touching the single-dose vial to the eye or to any other surface.
Aceclidine side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
VIZZ dosed once daily was evaluated for safety and efficacy in 466 participants with presbyopia in 2 randomized, double-masked, controlled phase 3 studies for 42 days (CLARITY-1, NCT05656027 and CLARITY-2, NCT05728944). VIZZ dosed once daily was also evaluated for long term safety in 217 participants with presbyopia in a separate randomized, double-masked, controlled phase 3 study (CLARITY-3, NCT05753189) for a 6-month duration.
The most common reported adverse reactions of participants were instillation site irritation (20%), dim vision (16%), and headache (13%). Adverse reactions reported in > 5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%). The majority of adverse reactions were mild, transient, and self-resolving.
About this medicine
VIZZ (aceclidine ophthalmic solution) 1.44% is a cholinergic muscarinic receptor agonist supplied as a sterile, clear to opalescent, colorless to slightly yellow, and viscous ophthalmic solution containing 1.75% of aceclidine hydrochloride (equivalent to 1.44% aceclidine).
The chemical names for aceclidine hydrochloride are: 1) 3-Acetoxyquinuclidine Hydrochloride; 2) 3-Quinuclidinyl Acetate Hydrochloride. Its molecular weight is 205.68 g/mol and its molecular formula is C
9H
15NO
2โ HCl.
Each mL of VIZZ contains aceclidine hydrochloride 1.75% (17.82 mg) as the active ingredient. Inactive ingredients in the ophthalmic solution are: polysorbate 80, mannitol, hypromellose, edetate disodium dihydrate, sodium citrate dihydrate, water for injection, and may also include hydrochloric acid and/or sodium hydroxide for pH adjustment to between 4.5 and 5.5, if necessary. VIZZ does not contain antimicrobial preservatives.
How it works: Aceclidine is a cholinergic muscarinic agonist that stimulates muscarinic receptors located on smooth muscles. โฆ
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 7aed8024-ad30-44d6-8f3b-63338ad3ce52. Read the full official label on DailyMed.